In our series of 37 patients with Kaposi's sarcoma, a larger than expected incidence of Americans of Italian and Jewish lineage was found, with 51% of Italian and 38% of Jewish background. Although a predominance of these two groups has been clearly shown previously, this may be the highest percentage of any series. In addition, 12, or 32%, of the patients were found to have concurrent diabetes mellitus. This association has been observed previously, but is not generally appreciated.

Fourteen patients with Kaposi's sarcoma (KSY were treated systemically with vinblastine sulfate in a low-dose regimen and compared with 23 patients reported in the medical literature. The therapeutic results in our series were excellent in terms of regression of cutaneous lesions. Vinblastine appears to be a drug that is well suited for the management of KS in an outpatient setting. Intravenous therapy may be supplemented with intralesional or intraarterial vinblastine.

No abstract

No abstract